Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: A nationwide retrospective cohort study

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 145-152

  Okumura, Yasuyuki ^a   Ito, Hiroto ^a   Kobayashi, Mika ^a   Mayahara, Ken ^b   Matsumoto, Yoshio ^b   Hirakawa, Junichi ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b Health Economics Committee of Japanese Association of Psychiatric Hospitals   (Japan)

Author keywords

Antipsychotic agents; Comorbidity; Diabetes mellitus; Prevalence

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CARPIPRAMINE; CHLORPROMAZINE; CLOCAPRAMINE; CLOSPIPRAMINE; EMONAPRIDE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; MOPERONE; NEUROLEPTIC AGENT; OLANZAPINE; OXYPERTINE; PEROSPIRONE; PERPHENAZINE; PHENOBARBITAL; PIMOZIDE; PIPAMPERONE; PROCHLORPERAZINE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZOTEPINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; DRUG SAFETY; FEMALE; HOSPITAL DISCHARGE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SURVEYS; HUMANS; JAPAN; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; REFERENCE VALUES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SEX FACTORS; STATISTICS AS TOPIC;

EID: 77952671418     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.02.1061     Document Type: Article

References (34)

1. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27(2):596-601. American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, North American Association for the Study of ObesityNorth American Association for the Study of Obesity.
2. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 2000, American Psychiatric Association, Author, Washington, DC.
3. Bushe C., Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br. J. Psychiatry 2004, 47(Suppl):67-71.
4. Chien I.C., Hsu J.H., Lin C.H., Bih S.H., Chou Y.J., Chou P. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr. Res. 2009, 111(1-3):17-22.
5. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004, 37(1):1-11.
6. Cohen D., Dekker J.J., Peen J., Gispen-de Wied C.C. Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment. Eur. Neuropsychopharmacol. 2006, 16(3):187-194.
7. Cohen D., Stolk R.P., Grobbee D.E., Gispen-De Wied C.C. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006, 29(4):786-791.
8. De Hert M., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens J. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin. Pract. Epidemol. Ment. Health 2006, 2:14.
9. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000, 26(4):903-912.
10. Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry 2005, 6(3):132-191.
11. Holt R.I., Bushe C., Citrome L. Diabetes and schizophrenia 2005: are we any closer to understanding the link?. J. Psychopharmacol. 2005, 19(6 Suppl):56-65.
12. Holt R.I., Peveler R.C., Byrne C.D. Schizophrenia, the metabolic syndrome and diabetes. Diabet. Med. 2004, 21(6):515-523.
13. Hung C.F., Wu C.K., Lin P.Y. Diabetes mellitus in patients with schizophrenia in Taiwan. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29(4):523-527.
14. Kobayashi, M., Ito, H., Okumura, Y., Mayahara, K., Matsumoto, Y., Hirakawa, J., submitted for publication. Hospital readmission and first-time admitted patients with schizophrenia: smoking patients had higher hospital readmission rate than non-smoking patients.
15. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
16. Lipscombe L.L., Levesque L., Gruneir A., Fischer H.D., Juurlink D.N., Gill S.S., Herrmann N., Hux J.E., Anderson G.M., Rochon P.A. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch. Intern. Med. 2009, 169(14):1282-1289.
17. Long J.S. Regression Models for Categorical and Limited Dependent Variables 1997, Sage Pubns, Thousand Oaks, CA.
18. Mayahara, K., Matsumoto, Y., Hirakawa, J., Ito, H., 2007. Effectiveness of day care and antipsychotics for discharged patients with schizophrenia, Melbourne.
19. The national health and nutrition survey in Japan (in Japanese) 2006, Ministry of Health, Labour and Welfare of Japan, Author, Tokyo.
20. Mukherjee S., Decina P., Bocola V., Saraceni F., Scapicchio P.L. Diabetes mellitus in schizophrenic patients. Compr. Psychiatry 1996, 37(1):68-73.
21. Murasaki M., Koyama T., Atsumi Y., Kadowaki T. Proposal of monitoring guidance for blood glucose in patients treated with second generation (atypical) antipsychotics (in Japanese). Jpn. J. Clin. Psychopharmacol. 2008, 11(6):1139-1148.
22. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care 2003, National Institute for Clinical Excellence, Royal College of Psychiatrists and the British Psychological Society, London.
23. Okumura Y., Misawa F., Nakabayashi T., Ito H. Pharmacotherapy of atypical antipsychotics and risk for diabetes in schizophrenia: a meta-analysis (in Japanese). Jpn. J. Clin. Psychopharmacol. 2010, 13:317-325.
24. Philippe A., Vaiva G., Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. Eur. Psychiatry 2005, 20(Suppl 4):S340-S344.
25. R: A Language and Environment for Statistical Computing 2008, R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria.
26. Regenold W.T., Thapar R.K., Marano C., Gavirneni S., Kondapavuluru P.V. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J. Affect. Disord. 2002, 70(1):19-26.
27. Rouillon F., Sorbara F. Schizophrenia and diabetes: epidemiological data. Eur. Psychiatry 2005, 20(Suppl 4):S345-S348.
28. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160(2):284-289.
29. Sernyak M.J., Gulanski B., Leslie D.L., Rosenheck R. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J. Clin. Psychiatry 2003, 64(5):605-608.
30. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008, 192(6):406-411.
31. Subramaniam M., Chong S.A., Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can. J. Psychiatry 2003, 48(5):345-347.
32. Suvisaari J., Perala J., Saarni S.L., Harkanen T., Pirkola S., Joukamaa M., Koskinen S., Lonnqvist J., Reunanen A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(3):129-136.
33. Tabata H., Kikuoka M., Kikuoka H., Bessho H., Hirayama J., Hanabusa T., Kubo K., Momotani Y., Sanke T., Nanjo K., et al. Characteristics of diabetes mellitus in schizophrenic patients. J. Med. Assoc. Thai. 1987, 70:90-93.
34. Voruganti L.P., Punthakee Z., Van Lieshout R.J., MacCrimmon D., Parker G., Awad A.G., Gerstein H.C. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study. Schizophr. Res. 2007, 96(1-3):215-222.